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The complex interactions between tumors and
their microenvironment remain to be elucidated.
Combining large-scale approaches, we examined
the spatio-temporal dynamics of 28 different immune
cell types (immunome) infiltrating tumors. We found
that the immune infiltrate composition changed at
each tumor stage and that particular cells had a
major impact on survival. Densities of T follicular
helper (Tfh) cells and innate cells increased, whereas
most T cell densities decreased along with tumor
progression. The number of B cells, which are key
players in the core immune network and are associ-
ated with prolonged survival, increased at a late
stage and showed a dual effect on recurrence and
tumor progression. The immune control relevance
was demonstrated in three endoscopic orthotopic
colon-cancer mouse models. Genomic instability of
the chemokine CXCL13 was a mechanism associ-
ated with Tfh and B cell infiltration. CXCL13 and
IL21 were pivotal factors for the Tfh/B cell axis corre-
lating with survival. This integrative study reveals the
immune landscape in human colorectal cancer and
the major hallmarks of the microenvironment associ-
ated with tumor progression and recurrence.
INTRODUCTION
Cancer is a complex disease involving interactions between the
tumor and the immune system (Finn, 2008). We have reported
that a coordinated Th1 cell and cytotoxic immune infiltration
both in the center and in the invasive margin of human colorectal782 Immunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc.tumors is associated with a favorable clinical outcome in terms
of local tumor spreading, disease-free survival, and overall sur-
vival. In contrast, a low density of T cells was associated with a
poor prognosis (Galon et al., 2006; Galon et al., 2007; Page`s
et al., 2005). In fact, the various clinical andhistopathologic criteria
currently available (Jemal et al., 2006;Weitz et al., 2005) show that
the T cell immune infiltrate is the most important predictive crite-
rium for patient survival (Atreya and Neurath, 2008; Bindea et al.,
2010; Galon et al., 2006; Mlecnik et al., 2011; Page`s et al., 2009).
This association is also supported by mouse models of immuno-
surveillance and immunoediting (Koebel et al., 2007; Schreiber
et al., 2011; Shankaran et al., 2001; Smyth et al., 2006). Advances
in cellular immunology and tumor biology are facilitating new
approaches toward adoptive T cell therapy (June, 2007b) and
leading to promising results (June, 2007a). Analysis of colorectal
and other tumors have confirmed the positive impact of T cells
(reviewed in (Fridman et al., 2012)). However, cells infiltrating
tumors are highly heterogeneous, and most of the components
ofmyeloid and lymphoid compartments are represented. Analysis
of how immune cells other than Th1 and cytotoxic lymphocytes
affect clinical outcome has often yielded contradictory results. In
addition, no comprehensive analysis of the local coordination of
the various immune compartments, nor of the genome plasticity
of cancer cells, has been conducted in the same patients.
To gain deeper insights into tumor progression and tumor
recurrence mechanisms in human colorectal cancer (CRC), we
performed integrative analyses. Our systems approach to can-
cer is grounded in the idea that the host-immune response and
tumor progression reflect perturbations at the gene and protein
level and that regulatory networks differ over time and with clin-
ical outcome (Mlecnik et al., 2010b; Wang et al., 2004; Wang
et al., 2008).
To understand the complex spatiotemporal dynamics of the
tumor-immune interaction during tumor progression, we used
several experimental approaches and visualization methods.
We investigated most of the tumor-immune infiltrates as well
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tion of immune responses. We built a compendium of mRNA
transcripts specific for most innate and adaptive immune cell
subpopulations that constituted the ‘‘immunome.’’ We analyzed
the immunome of 105 patients with colorectal carcinoma. We
also used quantitative real-time PCR (qPCR) and tissue microar-
rays (TMAs) to evaluate the immune reaction within the center
(CT) and at the invasive margin (IM) of the tumor and to examine
its changes as a function of the tumor stage. The impact on
patient survival of all immune cells infiltrating tumors was shown.
Chromosomal instability of all chemokines and chemokine
receptors was evaluated, and mechanisms associated with
major immune cell infiltration were revealed through the use of
human samples, in vitro assays, and several mouse models of
CRC. Here, we present the immunome analysis as what we refer
to as the ‘‘immune landscape,’’ a hallmark of the tumor microen-
vironment associated with tumor progression and recurrence in
CRC patients.
RESULTS
Analysis of Immune Cell Subpopulations Defining the
Immunome
We characterized the immune reaction in the tumor microenvi-
ronment by establishing a reference, the immunome com-
pendium. In order to build this compendium, we used publicly
available data from purified immune cell subsets (Chtanova
et al., 2005; Hyrcza et al., 2007; Wendt et al., 2006) to compare
the transcriptional profile of most immune cell subpopulations.
We investigated both innate immune cells (dendritic cells
[DCs], immature DCs [iDCs], activated DCs [aDCs], eosinophils,
mast cells, macrophages, natural killer cells [NKs], NK CD56dim
cells, NK CD56bright cells, and neutrophils) and adaptive immune
cells (B, T helper 1 [Th1], Th2, T gamma delta [Tgd], CD8+ T, T
central memory [Tcm], T effector memory [Tem], and T follicular
helper [Tfh] cells). Additionally, data from normal mucosa (An-
cona et al., 2006) and colon cancer cell lines (Provenzani et al.,
2006) were integrated with the immune data in a comprehensive
collection of microarray data sets. Highly distinctive transcrip-
tional profiles of all cell types were selected (Figure 1A; see
also Table S1 in the Supplemental Information available with
this article online). The selection was completed with known
markers of subpopulations of T helper 17 (Th17) cells, regulatory
T (Treg) cells, and blood and lymphatic vessels present in the
tumor microenvironment but not included in this collection. A
total of 577 genes (681 Affymetrix probes) constituted the normal
reference that was further used for investigation of the immune
reaction in CRC patients.
We then performed microarray expression experiments and
analyzed the 681 probes in tumors from 105 CRC patients
and five histologically normal colon mucosa. Two clusters of pa-
tients were found, and 372 probes were significantly differen-
tially expressed between the two groups (Figure 1B). As shown
in Figure S1A and Table S2, the patterns of expression that
characterized the group of patients with significantly prolonged
disease-free survival (cluster 1) were different than those that
characterized patients with an unfavorable outcome (cluster 2)
(hazard ratio [HR] = 2.0 (95% CI, 1.1–3.7; p = 0.02). An overrep-
resentation of highly expressed genes specific for T cell popu-lations and subpopulations of Th1, Tgd, cytotoxic T cells as
well as for macrophages and mast cells was significantly asso-
ciated with the patient cluster 1 (all p values < 0.05). In compar-
ison, patient cluster 2 showed an overrepresentation of highly
expressed genes specific for eosinophil, Tcm, Th2, Th17,
Treg, and NK cell subpopulations (all p values < 0.05). As
compared to the cancer cell line markers that associated to
cluster 2, lymph vessel and normal mucosa makers were signif-
icantly overrepresented in cluster 1 (all p values < 0.05). Func-
tional analysis of the immune signature was performed with
CluePedia and ClueGO (Bindea et al., 2013; Bindea et al.,
2009; Figure S1B). The genes highly expressed in cluster 1
were mainly associated with cytotoxic T cell surface molecules,
T helper cell surface molecules, and chemokine-related terms,
and functions related to endothelial cell migration. In contrast,
cluster 2 patients showed a different immune pattern, involving
genes with roles in in IL-2 signaling and in the regulation of
adaptive immune responses. Thus, patients have diverse intra-
tumor immunome patterns that correlate with different clinical
outcomes.
Coordination of Immunome Gene Expression
We used a more sensitive method, qPCR, to investigate the
expression of 81 representative genes (selected from the 577
genes in Figure 1) in 153 CRC patients (Figure 2 and Table S3).
Most of the 81 selected genes were known immune membrane
receptors. When we compared the expression of these 81
markers on immunome-positive cell types versus all other nega-
tive cells, the median increase was 92-fold (95% confidence in-
terval [CI]: 4.5–490), showing the strong overexpression of these
genes in a specific cell type. Herein, multiple techniques and
experimental approaches (including DNA microarray [Affyme-
trix], quantitative PCR [qPCR], fluorescence-activated cell sort-
ing [FACS], immunohistochemistry, and mouse models) were
used, and strong correlations were found with different ap-
proaches (Figure S2). Markers specific for the same cell type
strongly correlated and clustered together (Figure 2 and Fig-
ure S3). A positive correlation between markers of different cell
types was found as well, and functional associations of comodu-
lated genes were defined (Figure 2 and Table S4). Unsupervised
clustering revealed three main functional associations (clusters
1, 2, and 3) at the tumor microenvironment. SW480 cancer cells,
neutrophils, and Th17 cell markers grouped in cluster1 and did
not correlate with other cell-type markers. Two other clusters
showed adaptive (cluster 2) and innate (cluster 3) immune cell
marker predominance. Within the innate cluster, overrepresen-
tations of markers of mast cells and eosinophils (cluster 4), den-
dritic cells (cluster 5), and macrophages (cluster 6) were found.
The adaptive immune cluster (T, B, and Tfh cells) functionally
grouped into different subclusters (clusters 7, 8, and 9). Partic-
ular innate and adaptive markers were correlated with one
another. NK cell markers clustered with CD8+ T cell markers, re-
flecting the common cytotoxic properties of these cells (cluster
7). Within the adaptive cluster, besides a coordination of T cell
subpopulation markers, B cells and Tfh cell markers (cluster 8)
presented a strong and significant (p < 0.0001) correlation with
the T cell markers (Table S4). Th1 and overall T cell markers
formed cluster 9. Thus, a coherent profile emerged from the un-
supervised clustering of the gene-gene correlation matrix. MajorImmunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc. 783
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Figure 1. Immunome Gene Selection
(A) Transcriptome data for purified adaptive and innate immune cells (immunome), a colon cancer cell line, normal mucosa, blood, and lymph vessels were
normalizedwith Genesis (Sturn et al., 2002). Five hundred seventy-seven cell-type-specific genes (681 Affymetrix probes) are shown. Highly expressed genes are
in red, and lowly expressed genes are in green. The 28 cell types are shown in a colored bar (right). This collection comprises, besides genes specific for particular
subpopulations, genes highly expressed by immune cell populations (DCs, T cells, T helper cells, and NK cells) and by cells with common cytotoxic properties
(cytotoxic cells: CD8 T cells, Tgd, and NK cells).
(legend continued on next page)
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Figure 2. Gene-Gene Correlation Matrix Characterizing the Tumor Microenvironment
Pearson-correlation matrix of 81 cell-type-specific genes tested by qPCR on 153 colorectal CRC patients. The correlation matrix was subjected to unsupervised
hierarchical clustering (Euclidean distance measurement, average linkage clustering). Each colored square within the figure illustrates the correlation between
two genes for all the patients. Red color illustrates a very strong positive correlation (r = 0.9, p < 0.00001), white no correlation (r = 0), and green a negative
correlation (r = 0.9). The distribution of cell types corresponding to the clustered genes is shown in a colored bar (top). Functional clusters of comodulated
markers are shown (left). For each cluster, the cell type overrepresentation was evaluated with a Fisher’s exact test (Table S4). Tumor recurrence analyses are
presented (right). Genes for which impact on disease-free survival was found to be significant by a log-rank test and that had HR < 1 (good impact on patient
outcome) are marked with a green square, and those with HR > 1 (bad outcome) are marked with a red square. See also Figures S2 and S3 and Tables S3 and S4.
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cell subpopulation markers within the tumor.
Knowing the strong impact of the T cell markers on patient
survival, we further investigated cells having a similar functional
profile in tumors. We performed additional quantitative qPCR
experiments to investigate how B cell markers might be associ-(B) Six hundred eighty-one probes were investigated in 105 CRC tumors and five d
clustered (Pearson uncentered algorithm, average linkage). Two patient clusters
significant difference (p value < 0.05) between patient clusters 1 and 2 are shown
green. See also Figure S1 and Tables S1 and S2.ated with patient survival. In the two groups of patients defined in
Figure 1B, with good (cluster 1) and bad (cluster 2) outcomes, we
analyzed major histocompatibility complex (MHC)-II-related
genes and B cell costimulation-related genes, as well as genes
related to T cells, Tfh cells, MHC-I, and inflammation. Patients
with prolonged survival had a significant increase in theistant normal colon (NC) samples. The data were normalized and hierarchically
were revealed. Three hundred seventy-two probes for which a t test showed a
. Highly expressed genes are shown in red, and lowly expressed genes are in
Immunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc. 785
Figure 3. Expression of MHC-, Costimulation-, and Inflammatory-Related Genes in CRC Patients from Clusters 1 and 2
Gene expression levels were assessed by qPCR and determined with Ct values (threshold cycle) normalized to 18S (dCT). Heat-map representation of the gene
clusters for different immune functions are shown. Genes are plotted from theminimal level of expression (blue) to the maximal level (red). TheMann-Whitney test
was used for comparison of the expression levels of each gene between patient groups.
Immunity
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T cells, and Tfh cells. In contrast, no significant difference was
found in the expression of MHC-I- and inflammation-related
genes (Figure 3).
The tight coordination of adaptive immune markers found at
the tumor microenvironment could be a fundamental feature of
the host defense in response to tumor development.
Analysis of Immune Subpopulations In Situ
The expression of markers for Tfh cells, a cell type known to
‘‘help’’ the generation of B-cell-mediated immune responses
(King et al., 2008), showed a strong correlation with the B cell
markers. Using tissue microarrays, we next examined the
different immune cell subpopulations in the CT and at the IM of
107 CRC patients (Figure 4A; see also Figure S4). All the immune
cell subsets tested were found within the tumor at varying cell
densities. Furthermore, the composition of the immune infiltrate
was different in the CT versus the IM region. It was of interest to
note the predominance of the B cells at the IM compared to the
CT. Greater numbers of the T cell subsets (CD3, CD45RO, CD8,
CD57, and CXCR5) were also present at the IM. Using four-color
fluorescent immunohistochemistry, we confirmed the presence
of T cells, Tfh cells, and B cells in situ within CRC tumors (Fig-
ure 4B). Importantly, the immune reaction appeared to evolve
with tumor progression from stages T1 to T4 (Figure 4C). Most
of the T cell subpopulation markers, CD3, CD8, CD57,
CD45RO, and FOXP3 (with the exception of those for Tfh cells),786 Immunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc.were highly expressed at early stage (T1) and then decreased
with tumor progression. In contrast, the density of B cells
increased with tumor stage, as did that of the innate immune
cells such as neutrophils, mast cells, iDCs, pDCs, and
macrophages.
We have visualized, in a format that we refer to as
‘‘flower plot,’’ the n-fold change of the density of each of the
immune cell markers as a function of the tumor stage at
both the CT and the IM (Figure S4). Each transition stage
was associated with a new immune profile at the tumor site.
Immune subpopulations varied in density profiles at the CT
and IM with time and tumor progression. The transition of tumor
stages T1–T4 was characterized by the increase or decrease of
immune cell densities. The evolution and spatial distribution of
these subpopulations in tumor regions might affect tumor
recurrence.
Importance of the Intratumoral Immune Landscape
We next studied the contribution of the immune landscape
to tumor recurrence and showed that distinct immune profiles
are associated with significantly different prognoses (relapse
risks) (Figure 5). Most of the T cell markers, including CD8+
for T, Th1, and Tem cells, were logrank significant and associ-
ated with a good prognosis (disease-free survival, DFS;
HR < 1), confirming our previous reports (Galon et al., 2006).
We found that a high expression of Tfh and B cell genes was
also strongly associated with a good prognosis (Table S4 and
AB C
Figure 4. Analysis of Intratumoral Immune
Cell Densities Relative to the Tumor Stage
(A) Immune cell infiltrates from 107 CRC patients
were analyzed by tissue microarray (TMA). T cells
(quantified with marker CD3), cytotoxic T cells
(CD8), memory T cells (CD45RO), Treg cells
(FOXP3), activated T or NK cells (CD57), Tfh cells
(CXCR5), Th17 cells (IL-17), B cells (CD20), iDCs
(CD1a), pDCs (IL3RA), macrophages (CD68), mast
cells (Tryptase), neutrophils (granulocyte), blood
vessels (ENG), and lymph vessels (PDPN) were
quantified by immunohistochemistry. For cells
marked by CD8 and CD68, the cell density was
evaluated as total cell density of extratumoral cells
(within the stroma) and intratumoral cells (within
the tumor glands). The density of the cells was
recorded as the number of positive cells per mm2
surface area by use of a dedicated image-analysis
workstation (Spot Browser ALPHELYS). The mean
(± SEM) cell densities in the CT (light blue bars) and
IM (orange bars) were compared. The tested
marker for each cell type is shown in the top of the
bars. In dark blue, the median cell count/mm2 is
shown. The test that was suggested on the basis
of the Shapiro test result was the Wilcoxon-Mann-
Whitney test for all the cell types. ***p < 0.001,
**0.001% p < 0.05, and *0.05% p < 0.1.
(B) Immune cell populations present at the tumor
site were visualized by four-color immunohisto-
chemistry. Tumors were stained for CD3-positive
T cells (green), CD20-positive B cells (pink),
CXCR5-positive Tfh cells (red), and the nucleus
(DAPI, blue). Tfh cells (double stained for CD3 and
CXCR5) are present at the tumor site in close
proximity to B cells and other T cells.
(C) The evolution in time of the mean cell density
(TMA data) in 107 CRC patients. The data were
normalized and hierarchically clustered (Manhat-
tan distance, single linkage). Highly expressed
genes are shown in red, and lowly expressed
genes are shown in green. The T cell markers
(CD57, CD3, CD8, FoxP3, and CD45RO) and
lymph-node marker (PDPN) are clustered together
(blue cluster). Their expression decreased with
tumor stage from T1 to T4. In contrast, the mean
expression of CD20-positive B cells (represented
in red) increased with progression to stage T4. A
similar pattern can be seen for the innate cell
markers (CD68, Tryptase, IL3RA, CD1a, and
granulocyte), CXCR5 (Tfh cells), and ENG, the
blood vessel marker (brown cluster). See also
Figure S4 and Table S4.
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NK cells, pDCs, aDCs, and eosinophils also exerted a moderate
positive effect. In contrast to all other T cell subpopulations, Th17
cells negatively influenced the patient outcome (DFS, HR > 1, p <
0.05).
Correlation and survival analyses of the 81 qPCR genes were
integrated in a Cytoscape (Shannon et al., 2003) network. Be-
sides gene-gene interactions, complex interrelations be-
tween different immune cell types were revealed (Figure S3). A
strong positive correlation between adaptive immune cell
markers was present (Table S5) and had a positive impact onthe patient outcome. Although associated with the adaptive
network, macrophages had no prognostic effect. The other
immune cell populations had weaker correlations with the adap-
tive immune cell cluster and between themselves. All these re-
sults were confirmed at the protein level via in situ immunohisto-
chemistry (Figure 5).
Based on the TMA data, a 3D visualization of the immune
landscape in CRC allowed us to investigate the immune cell
density patterns over time in situ and their impact on the
patients’ disease-free survival (Figure 5 and Movie S1). The
network topology showed a clear separation between the twoImmunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc. 787
AB
Figure 5. The Immune Landscape in CRC
3D visualization of the CRC immune landscape based on TMA data in 107 CRC patients. Cell-type-specific markers were evaluated in the center of the tumor (CT,
in blue) and at the invasive margin (IM, in yellow) of the tumor. The connecting lines (edges) represent the correlation between all the investigated cell-type
densities. The proximity of the peak topologies illustrates the degree of correlation. The edges with r < 0.35 and r > 0.35 were filtered out. Only positive cor-
relation remained after filtering. The X,Y force-directed topology was created with the Organic algorithm fromCytoscape and is based on the correlation between
nodes.
(A) The height of individual peaks (z axis) represents themean cell density (peak heights in cells/mm2). Blue, orange, and red, respectively, distinguish the T cell, B
cell, and macrophage markers included in the network.
(B) The height of individual peaks (z axis) represents the clinical outcome visualized by log2-transformedHRs for DFS. Green: HR < 1 (good outcome). Red: HR > 1
(bad outcome). See also Figure S5, Tables S5 and S6, and Movie S1.
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mune cell density pattern, as shown by the distribution of
blue (CT) and yellow (IM) peaks. In each tumor region, a sub-
network of T cell subpopulations (CD3 cells, CD8 cells, memory
T cells, Treg cells, and activated T cells) could be found (Fig-
ure 5A). This analysis also revealed several unexpected
observations. Within the tumor center, it was interesting to
note the close correlation between B cells (CD20) and the
T cell subset network (even though the actual number of
B cells was small). There was an increased fraction of intra-
tumoral CD8+ T cells among cytotoxic T cells in the CT com-
pared to the IM (34% versus 16%). At the tumor margin the
density of B cells was elevated and correlated with the IM
T cell network and, in particular, with memory T cells (indicated
by marker CD45RO). Tfh cells (indicated by marker CXCR5)
were infiltrating the tumor center were closely correlated with
T cell subsets measured in the tumor margin. Furthermore,
the macrophages were the only innate cells associated with
the T cell network in both tumor regions, whereas the density
of lymphatic vessels (quantified with marker podoplanin
[PDPN]) correlated with the CT part of the T cell network. In
contrast, other cell types, such as granulocytes, mast cells,
and Th17 cells, were not associated with the core T cell
network and showed no difference in their density between
the CT and the IM. The density of iDCs and pDCs in the CT
was not correlated with the density measured in IM. The local
coordination shown in the T cell network underlines the exis-
tence of tumor-microenvironment compartments with different
compositions that might influence the mobility and activity of
T and B cells along with tumor progression. The evolution
of the individual cell-type density during tumor progression
(from T1 to T4 stages) can be visualized in a 3D animation
(Movie S1).
We showed the impact of individual cell types on the DFS as
reflected by peaks representing the HR (Figure 5B). It is evident
that virtually all of the T cells in the network (except for Th17
and Tfh cells in the IM) exert a marked positive effect on the
clinical outcome. A high density of B cells correlated with pro-
longed survival (CD20-CT CD20-IM HiHi versus LoLo, HR = 3.7
[95% CI: 1.9–7.6], p < 0.002). The good prognostic impact of
B cells was further validated in an independent cohort of 415
patients, (HR = 2.2 (95% CI: 1.4–3.6), p < 0.05). Furthermore,
a significant beneficial effect of IM B cells on DFS was
observed when the IM B cell densities were combined with
T cells densities (Table S6). In this regard, it was of interest
that the Tfh cells (as shown by the density of CXCR5+ cells
in the CT) also exerted a positive effect. From the innate im-
mune cells, only neutrophils and mast cells at the IM showed
a moderate positive impact on patient survival, whereas macro-
phages and iDCs were slightly (almost but not quite signifi-
cantly) associated with a bad outcome. The presence of
lymphatic vessels was beneficial for patient survival. The strong
correlation of B cells and Tfh cells, components of cells of
adaptive immunity, as shown with both qPCR and TMA ana-
lyses underlines the importance of those cells in strengthening
the protection against tumor recurrence (Deola et al., 2008).
These adaptive immune cells are likely to ensure long-term
survival of the patients because they can acquire a memory
phenotype.Mechanisms Associated with CXCL13 Expression and
Intratumoral Densities of Lymphocytes
Given the impact of the local immune reaction on a patient’s
survival, it was of major importance to understand mechanisms
resulting in high or low densities of specific immune cells within
the tumor. Genomic instability that generates genetic diversity
could influence the generation of immune responses. We thus
investigated the accumulation of amplifications or the presence
of deletions of the chromosomal regions where all (n = 53) che-
mokines and chemokine receptors are located. The chromo-
somal instability (CIN) in CRC tumors was analyzed by array
comparative genomic hybridization (aCGH). As expected, we
identified many gains and losses of chromosomal regions, as
has been previously reported in colorectal cancer; for example,
a gain of 8q and a loss of 8p has been reported (Tsafrir et al.,
2006). An overview of the chromosomal location of the chemo-
kines and their corresponding frequency of gains and losses in
109 CRC patients is shown (Figure 6A). The most frequently
(>15%) amplified chemokines were located in chromosomes 7,
16, and 19. Frequently deleted cytokines (>15%) were located
in chromosome 4 and 17.
The genomic alterations occurring in tumor cells could pro-
voke changes in local chemokine expression. To evaluate this
hypothesis, we compared the expression of the chemokines in
patients with or without genomic alterations. We found nine che-
mokines with significantly different expression in patients with
aberrations than in those without (Figure 6B). Two chemokines
(CCL24 and CXCL9) showed significantly higher expression in
patients who had a gain, whereas significantly lower expression
was observed for seven deleted chemokines (CCL1, CCL26,
CCR6, CXCL2, CXCL12, CXCL13, CXCL16) (Figure 6B). Using
immunohistrochemistry, we showed that tumor cells expressed
CXCL13 (Figure 6C). We further illustrated that patients with
CXCL13 deletion had decreased CXCL13 expression levels (Fig-
ure 6D). We stratified patients into three groups based on their
genomic alterations (gain, loss, no aberration). Strikingly, survival
analysis in patients with aberrations (HR = 2.44 [95% CI: 1.2–
4.9], p < 0.05) versus patients without genomic alterations re-
vealed only two chemokines (CXCL2 and CXCL13) that
conferred a significantly different risk to relapse when they
were deleted (Figure 6B). Thus, patients with CXCL13 deletion
have a significantly higher risk of relapse than do patients without
aberrations, as illustrated by Kaplan-Meier curves (Figure 6E).
We hypothesized that CXCL13 deletion within colorectal tumors
could be a mechanism resulting in low densities of B cells and
Tfh cells. We investigated the in situ densities of B cells and
Tfh cells within different tumor regions from colorectal tumors
(Figure 6F). Patients with CXCL13 deletion showed a lower
density of B cells and Tfh cells in the IM region. To demonstrate
the impact of CXCL13 produced by tumor cells, we isolated
fresh tumor cells from colorectal tumors and cultured them for
24 hr. We used supernatants from tumor cells to induce
the in vitro migration of immune infiltrating cells from the same
tumors. CD4+ T cells migrated when subjected to tumor cell
supernatants, whereas NK cells and macrophages did not.
Finally, anti-CXCL13 antibodies inhibited this migration, demon-
strating the chemoattractant role of CXCL13 within tumors
(Figure 6G). To validate the importance of Tfh-cell-related major
soluble factors, we investigated the expression of CXCL13, IL21,Immunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc. 789
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Figure 6. Genomic Alterations in CRC Pa-
tients
(A) The chromosomal location and the frequency
of genomic alterations of 53 chemokines and
chemokine receptors within colorectal tumors.
Genomic alterations were investigated in 105 pa-
tients by aCGH. The shown frequency scale
ranges from 0%–30%. The frequency of gains and
losses is represented in red and green, respec-
tively. The chemokine genes with alterations in
more than 15% of the patients are underlined.
(B) Venn diagram showing the number of t-test-
and log-rank-test-significant genes among the 53
chemokines. t-test-significant cytokines with a
gain (n = 2, red) or loss (n = 7, green) are shown.
The expression level in aberration-containing pa-
tients compared to patients without aberrations is
shown on the right side. Among all chemokines, 11
were log-rank-test significant, and among these,
only 2 (CXCL2 and CXCL13) were also t-test sig-
nificant with regard to their expression.
(C) CRC sections were assessed im-
munohistochemically with triple fluorescent stain-
ings with DAPI (blue), a mouse anti-human CD3
antibody (green), and a mouse anti-human
CXCL13 antibody (red).
(D) Histograms representing the mean ± SEM
CXCL13 expression relative to that in patients
without aberrations is shown. No aberration (No,
white) and deletion (Del, green) patient groups are
represented.
(E) Kaplan-Meier (KM) curves for DFS for patients
with a chromosomal deletion (green) of CXCL13
versus patients without genetic alterations (black).
(F) Histograms represent the mean densities ±
SEM of CD20+ and CXCR5+ cells as the
number of positive cells/mm2 of tissue at the
IM (CD20-IM and CXCR5-IM) CT (CD20-CT and
CXCR5-CT) of tumors from CRC patients. The
mean density is represented for patients with a
chromosomal deletion of CXCL13 (green columns)
versus patients without genetic alterations
(white columns).
(G) Tumor cells and tumor-infiltrating lymphocytes
(TILs) were isolated. TILs were seeded in transwell
chamber containing patient-matched tumor cell
supernatants with or without anti-CXCL13 neutralizing antibody. Migrating cells (indicated by markers CD45, CD3, CD4, NKP46, and CD68) were analyzed
by flow cytometry after 24 hr. Data are presented as means ± SEM.
(H) KaplanMeier curves for DFS for CXCL13 (the B cell chemoattractant), MS4A1 (CD20, a B-cell-specific gene), and IL21 showed significant separation between
the group of highly expressed genes (Hi, red) versus the lowly expressed genes (Lo, black) at the minimum p-value cutoff.
Significantly different expression as well as log-rank significance are marked by an asterisk. See also Figure S6 and Table S6.
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DFS. High expression of B cell markers (CD19Hi versus CD19Lo
[HR = 1.95 (95% CI: 1.1–3.5)] and MS4A1 [HR = 2.76 (95% CI:
1.0–7.6)], p < 0.05) and of Tfh cell markers (CXCL13 [HR = 3.2
(95% CI: 1.7–6.0)] and CXCR5 [HR = 1.96 (95% CI: 1.1–3.5)],
p < 0.05) correlated with a significantly prolonged disease-free
survival time (Figure 6H and Table S6). We further analyzed the
mechanistic aspects of our findings. We correlated CXCL13
and IL21 expression with markers specific for immune cell sub-
populations. A strong intratumor association of these factors
with B, Tfh, Th1, and cytotoxic T cells was revealed. In contrast,
they were not correlated with other cell populations (Figure S6).
Thus, these results underline a mechanism by which CXCL13790 Immunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc.could affect the intratumor densities of major immune cell sub-
populations associated with the survival of the patients.
Loss of the Adaptive Antitumor Immune Response Is
Associated with Tumor Progression in Murine
Orthotopic CRC Models
In order to further analyze the role the adaptive anti-tumor
immune response, we developed a unique endoscopic ortho-
topic CRC model in mice. Mouse CRC cell line MC38 was
injected endoscopically into the colonic submucosa of syngenic
C57Bl/6 mice (Figure 7A). Tumor growth was monitored weekly
via endoscopy. Within a few weeks, tumor cells built a continu-
ously growing tumor mass in the intestinal wall. The morphology
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Figure 7. Immunosurveillance and CXCL13-CXCR5 Signaling in a Murine Orthotopic CRC Model
(A) The murine CRC cell line MC38 (104) was injected endoscopically into the submucosa of syngenic C57Bl/6 and Rag1/ mice (i–iv). Tumor growth was
monitored by endoscopy every week.
(B and C) H&E staining of murine MC38 (A) and human (B) CRC tissue sections. Representative images for murine and human CRC tissue sections are shown.
Immune = area showing an immune cell infiltration at the tumor margin. Tum = tumor center.
(D) Normalized gene expression of various markers of the adaptive immune response. n = 3 per group. Data are presented as means ± SEM.
(E) Endoscopic scoring of tumor growth after the endoscopic injection of MC38 cells (104) into the submucosa of C57Bl/6 and Rag1/ mice. Endoscopy was
performed at the indicated time points. The experiment was repeated twice. n = 5 per group. Data are presented as means ± SEM.
(F) Tumor growth in C57Bl/6 mice (i) and Rag1/ mice (ii) was monitored by endoscopy at 3 weeks.
(G and H) Endoscopic scoring of tumor growth after 3 weeks of endoscopic injection of MC38 cells (104) into the submucosa of C57Bl/6 and Cxcr5/mice. Data
are presented as means ± SEM.
(I) Endoscopic scoring of tumor growth after the endoscopic injection of MC38 cells (105) with or without injection of recombinant CXCL13 into the submucosa of
wild-type mice.
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the tumors show infiltrative growth through the mucosa and an
immune response both within the tumor and at the tumor margin
(Figures 7B and 7C).
For a functional analysis of the adaptive immune system dur-
ing CRC progression, we exposed Rag1/ and wild-type mice
to the endoscopic orthotopic tumor model. As expected, tumors
of wild-type mice expressed various markers (CD8, CD4,
CXCR5, and CXCL13) of the adaptive immune response; these
markers were expressed to a markedly lower level in Rag1/
mice (Figure 7D). The markers included the chemokine
CXCL13 and its receptor CXCR5, suggesting a contribution of
CXCL13 signaling and Tfh-B cell interactions to the adaptive
anti-tumor immune response. Importantly, the growth of ortho-
topic MC38 tumors was significantly accelerated in Rag1/
mice in comparison to wild-type mice and therefore indicated
a functionally relevant immune control in a CRC mouse tumor
model (Figures 7E and 7F). To validate these findings, we used
two additional mouse models. Cxcr5/ mice were subjected
to endoscopic orthotopic injection of tumor cells. These mice
presented with an accelerated tumor growth compared to
growth in wild-type mice (Figures 7G and 7H). Finally, we in-
jected recombinant CXCL13 endoscopically within the colonic
submucosa of wild-type mice. Whereas all control mice (5/5)
experienced tumor growth, 80% (4/5) of CXCL13-treated mice
experienced tumor rejection (Fisher exact-test p < 0.05 at weeks
2.5 and 3 after injection) (Figure 7I). Thus, the good prognostic
values of cytotoxic T cells, CXCL13, Tfh, and B cells were
confirmed in murine orthotopic CRCmodels showing decreased
tumor burden.
DISCUSSION
Uncovering the complex interactions of tumors with their micro-
environment is of major importance in understanding defense
against cancer (Galon et al., 2013). After characterizing the ma-
jority of the immune subsets infiltrating colorectal tumors, we
placed the immune-tumor interface into a spatiotemporal
context. This led to a new perspective of host defense, the im-
mune landscape within the tumor, and revealed a central role
of Tfh and B cells.
Herein, we answered four questions. First, which immune cell
subpopulations present within the tumor, evolved over time, and
are associated with tumor progression from stages T1 to T4?
Second, among all immune cells, which are the important ones
for tumor recurrence and patient survival? Third, can we under-
stand the spatiotemporal dynamics of the immune reaction in
order to open new therapeutic perspectives at different stages
of the disease? Fourth, which mechanisms are associated with
different densities of intratumor immune cells?
This comprehensive analysis of the most innate and adaptive
immune cells infiltrating tumors provides the most complete pic-
ture of the immune reaction in human cancer so far. Highly ex-
pressed markers of purified immune cell subsets comprised a
compendium; a resource useful for scientists wishing to analyze
immune cells. Using the immunome, we investigated the
complexity of the immune signature in colorectal cancer tumors.
The caveat, however, is that the correlations we observed could
be due to the contribution of multiple factors. The correlation792 Immunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc.among genes could reflect variation in cell frequencies. Contrary
to this, within the tumor microenvironment, specific immunome
genes could also be expressed in other cell types. Gene expres-
sion might be prone to bias when applied to extremely heteroge-
neous and dynamic systems, where the gene expression profile
of pure samples cannot be considered an accurate parameter
for normalization. This is the case for tumor specimens, where
the gene-expression profiles in predefined cell subsets can
dramatically change under the influence of cytokines, chemo-
kines, and additional neighboring cells within the tumor microen-
vironment. However, here the purified immune cells were
investigated in different activation states, and only the most
representative genes (those overexpressed regardless of the
activation status) were kept. Furthermore, in the immunome
compendium, genes were selected on the basis of being highly
expressed on a specific cell type, and those encoding known
specific immune cell markers (CD19, CD209, LAMP3, CD3E,
IFNG, and PRF1) were found; thus, there existed a robust valida-
tion of the selection criteria. Because of the limitations of gene
expression profiles, additional approaches, such as flow-cytom-
etry and immunohistochemistry, are recommended to validate a
deep characterization of the cellular components of a tumor
biopsy. In the current study, multiple techniques and experi-
mental approaches (DNA microarray [Affymetrix], qPCR, FACS,
IHC, and mouse models) were used. Importantly, concordant
results were found with all approaches, reinforcing our results
and conclusions.
We found that the immune infiltrates vary considerably from
tumor to tumor and that they evolve over time. In addition, we
present here the immune landscape in colorectal tumors and
its evolution with tumor progression. Variable densities (‘‘moun-
tains’’ and ‘‘hills’’) of immune cell subsets from the innate and
adaptive compartments are shown. Adaptive immune cells
functionally associate into a core network reflecting tumor re-
gions. The tight association of B and T cells could reflect how
B cells modulate T cell responses by presenting antigens,
providing costimulation, and secreting cytokines (Lund and
Randall, 2010). Densities of Tfh cells and most innate cells
rose only in early-stage tumors, whereas most T cell densities
decreased along with tumor progression. Importantly, B cells,
which are part of the core immune cell network and are associ-
ated with prolonged survival, increased at a late stage and had a
dual effect on recurrence and tumor progression. Distinct B cell
subpopulations found at the tumor microenvironment could play
different roles, protumoral or antitumoral (DeNardo et al., 2010;
Lund and Randall, 2010; Pape et al., 2011). In human colorectal
tumors, B cells were strongly correlated with Tfh cells and were
associated with a good prognosis. It is evident that virtually all of
the T cells in the network exert a marked positive effect on clin-
ical outcome, as do B cells. In this regard it was of interest that
the Tfh cells also exerted a positive effect. In contrast, macro-
phages, although part of the network and present at high
density, did not significantly affect tumor recurrence. A strong
and effective protection against relapse does not necessarily
depend on the density of the immune cells. Thus, immune cell
types, even at low density, have major importance for tumor
recurrence.
As recently reviewed (Tangye et al., 2013), Tfh cells mediate
B cell responses and might underlie immunological diseases
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Here, we investigated Tfh cells in solid tumors. The generation
of Tfh cells is mediated by IL-21 independently of other T
helper subsets (Nurieva et al., 2008). Through the IL-21
pathway, Tfh cells can give rise to transferrable memory cells
with plasticity; such cells differentiated after recall into con-
ventional effector helper T cells and Tfh cells. It was demon-
strated that Tfh cells were not terminally differentiated but
instead retained the flexibility to be recruited into other helper
T cell subsets and nonlymphoid tissues (Lu¨thje et al., 2012).
Interestingly, it was shown that early Th1 cell differentiation is
marked by a Tfh-cell-like transition (Nakayamada et al., 2011).
Furthermore, in a transgenic mouse model, IL-21 promotes
CD8+ CTL activity via the transcription factor T-bet (Sutherland
et al., 2013). Here we show major correlations between
CXCL13, IL-21, Th1, and Tfh cells, supporting the central role
of these factors in shaping the immune contexture in human
tumors.
Tfh cells provide help to B cells for the generation of germinal
centers and long-term protective humoral responses. Persis-
tent antigen and germinal center B cells sustain TFH cell re-
sponses and phenotype (Baumjohann et al., 2013). It is also
recognized that Tfh cells, display substantial flexibility and
plasticity and participate in shaping the T cell response (Can-
nons et al., 2013). CXCL13 is a hallmark of Tfh cells, and
CXCR5 has been identified as the receptor for CXCL13. It
was also reported that CXCL13 is an agonist for the human
CXCR3 receptor (Jenh et al., 2001). Thus, CXCL13 produced
within the tumor and by Tfh cells in proximity to the tertiary
lymphoid structure might also be a chemotactic agent for acti-
vated and memory T cells (Jenh et al., 2001; Mlecnik et al.,
2010b). Furthermore, IL-21 transgenic mice revealed that over-
expression of IL-21 directly promoted massive CD8+ memory
T cell accumulation (Allard et al., 2007). Indeed, we found a
strong and significant correlation between CXCL13, IL-21,
and these adaptive immune cells within the tumor-infiltrating
immune cell network.
Thus, we revealed herein major immune components from the
immune context associated with prolonged survival and the
absence of tumor recurrence (Angell and Galon, 2013; Fridman
et al., 2012; Galon et al., 2007). Through the production of
CXCL13, Tfh cells activate a positive loop associated with
increased intratumor densities of B, Tfh, Th1, cytotoxic, and
memory T cells in human colorectal tumors. Therefore, in addi-
tion to memory T cells (Galon et al., 2006), CXCL13 and IL-21
constitute, along with B cells and Tfh cells, the main antitumor
players. These adaptive immune cells are likely to ensure long-
term survival of the patients because they can acquire a memory
phenotype.
The results reported here add to those published previously
(Galon et al., 2006; Page`s et al., 2005) in several important
ways. By investigating most of the infiltrating immune cells, we
have been able to show a complete view of the immune
compartment of the tumor microenvironment. Among all the
immune cell subpopulations, B cells, T cells, and Tfh cells have
a major role in human colorectal cancer. Furthermore, we devel-
oped unique endoscopic orthotopic CRC mouse models to
demonstrate the role of the adaptive anti-tumor immune
response. The growth of mouse colon tumor cells was signifi-cantly accelerated in Rag1/ and in Cxcr5/ mice in compari-
son to wild-typemice, whereas tumors were rejected upon injec-
tion of CXCL13. This demonstrates the functional relevant
immune control in a CRC mouse model.
Spatiotemporal associations between immune populations
with a strong impact on patient survival were revealed. We pre-
sent sophisticated and synthetic methods of visualizing the
coordination and the strength of the host intratumoral immune
reaction along with tumor progression. Furthermore, integrating
the data into a network model representing the entire tumor
allowed us to interrogate dynamic networks in the three-dimen-
sional immune landscape along with tumor progression over
time and with tumor recurrence. The investigation of amplifica-
tions or deletions of all chemokines and chemokine receptors
within colorectal tumors revealed the major role of CXCL13
with regard to tumor recurrence and patient survival. Finally,
our data support a mechanism resulting in high or low densities
of intratumor Tfh and B cells within the IM of CRC tumors with
major clinical relevance.
The integrated analysis of diverse data sets might circumvent
challenges related to the staggering complexity of multifactorial
diseases such as cancer (Bindea et al., 2010). Researchers have
started to apply systems biology approaches to the study of the
immune system (Benoist et al., 2006; Gilchrist et al., 2006;
Tegne´r et al., 2006) and to modeling the immune response
(Kim et al., 2009). Emerging bioinformatics resources are now
aiding these types of analyses (Bindea et al., 2013; Bindea
et al., 2009; Shannon et al., 2003). At this point, we are reaching
a level where we may be able to capture the spatiotemporal
dynamics of complex disease processes. Our data highlight
the power of integrative cancer-immunology approaches to
help researchers understand the challenging issues of tumor
progression and tumor recurrence (Galon et al., 2013). The land-
scape representation greatly improved the visualization and the
interpretation of the coordination of the intratumoral immune cell
densities.
The information presented here might be of major clinical
importance. The different patterns of evolution of specific
immune cell subpopulations along with tumor progression
could lead to different strategies for the treatment of patients
with colorectal cancer. This knowledge can help scientists to
prioritize research, better understand disease pathogenesis,
and gain clues into how we might therapeutically manipulate
this system.
EXPERIMENTAL PROCEDURES
Colorectal Cancer Patients
Colorectal cancer patients who underwent a primary resection of their tumor
at the Laennec-HEGP Hospitals between 1996 and 2004 were reviewed and
previously described. Histopathological and clinical findings were scored
according to the Union for International Cancer Control TNM staging system
(Table S7). Ethical, legal and social implications were reviewed by an ethics
review board. All experiments were performed according to the Helsinki
guidelines.
Mouse Model
Endoscopic injection of murine MC38 colon tumor cells in the submucosa of
the colon of C57Bl/6, Rag1/, andCxcr5/mice. The needle was positioned
inside the working channel of the endoscope so that there would be no
damage to the colonic mucosa. After insertion of the endoscope, the tip ofImmunity 39, 782–795, October 17, 2013 ª2013 Elsevier Inc. 793
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a low number of cells (104–105) were injected into the submucosa. Recombi-
nant CXCL13 was injected similarly. During subsequent weeks, tumor growth
was analyzed via colon endoscopy.
Experiments
DNA microarray experiments were performed with Affymetrix U133A Plus
arrays. Quantitative real-time TaqMan PCR was performed with low-density
arrays and the 7900 robotic real-time PCR system (Applied Biosystems).
Immunohistochemistry on tissue microarray sections was performed as
previously described (Galon et al., 2006). Migration assays on fresh infiltrating
cells are described in detail in the Supplemental Information. aCGH was car-
ried out on a whole-genome oligonucleotide microarray platform (44B, Agilent
Technologies).
Datasets
The data sets used in this study are publicly available (ArrayExpress [Ancona
et al., 2006; Parkinson et al., 2007; Wendt et al., 2006], Gene Expression
Omnibus [Barrett et al., 2005; Hyrcza et al., 2007; Provenzani et al., 2006],
and Garvan Institute dataset [Chtanova et al., 2005]) and were all generated
with the HG-U133A Affymetrix platform. Supplemental Experimental Proce-
dures and any associated references are available in the online version of
the paper.
Statistical Analysis
Correlation matrices were created with Pearson correlation. All bar plots are
shown as mean ± standard error of the mean (SEM). The normality of the
data was tested with the Shapiro-Wilk test. For pairwise comparisons of para-
metric and nonparametric data, the Student’s t test and Mann-Whitney-Wil-
coxon rank-sum test, respectively, were used. The hazard ratio (Cox
proportional hazards model) and the log-rank test were used for comparing
disease-free and overall survival between patients in different groups. To
avoid over-fitting, we corrected hazard ratios and log-rank p values obtained
by the ‘‘minimum p value’’ approach by using the methods suggested by Hol-
lander et al. (Holla¨nder et al., 2004) and Altman et al. (Altman et al., 1994),
respectively. The predictive performance of each individual marker was as-
sessed by the Harrell’s concordance index (c index) (Harrell et al., 1996)
and time-dependent c index (CT index) derived from time-dependent ROC
analysis (Heagerty and Zheng, 2005). Throughout the text, a p value < 0.05
is considered statistically significant. All analyses were performed with the
statistical software R (survival package and risksetROC packages) imple-
mented as a statistical module in TME.db (Mlecnik et al., 2010a). Functional
and correlation analyses were performed with CluePedia and ClueGO (Bindea
et al., 2013; Bindea et al., 2009) within the Cytoscape framework (Shannon
et al., 2003).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, a
list of CEL files included in the immunome analysis, six figures, seven tables,
and one movie and can be found with this article online at http://dx.doi.org/
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